Enanta Pharmaceuticals (ENTA) Capital Expenditures Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.07% |
| Dec 31, 2025 | -5.32% |
| Sep 30, 2025 | 153.94% |
| Jun 30, 2025 | -122.09% |
| Mar 31, 2025 | 54.12% |
| Dec 31, 2024 | 78.10% |
| Sep 30, 2024 | 108.03% |
| Jun 30, 2024 | 12.18% |
| Mar 31, 2024 | 1.00% |
| Dec 31, 2023 | -9.61% |
| Sep 30, 2023 | 99.77% |
| Jun 30, 2023 | 30.68% |
| Mar 31, 2023 | 15.79% |
| Dec 31, 2022 | 95.33% |
| Sep 30, 2022 | 17.63% |
| Jun 30, 2022 | -19.47% |
| Mar 31, 2022 | -7.52% |
| Dec 31, 2021 | -45.46% |
| Sep 30, 2021 | 17.07% |
| Jun 30, 2021 | -20.04% |
| Mar 31, 2021 | -38.79% |
| Dec 31, 2020 | -38.84% |
| Sep 30, 2020 | -15.67% |
| Jun 30, 2020 | -13.83% |
| Mar 31, 2020 | -42.08% |
| Dec 31, 2019 | 13.77% |
| Sep 30, 2019 | -9.40% |
| Jun 30, 2019 | 42.61% |
| Mar 31, 2019 | 62.28% |
| Dec 31, 2018 | 122.34% |
| Sep 30, 2018 | -26.61% |
| Jun 30, 2018 | -90.13% |
| Mar 31, 2018 | 27.41% |
| Dec 31, 2017 | 58.78% |
| Sep 30, 2017 | 16.09% |
| Jun 30, 2017 | 73.60% |